Integra LifeSciences (IART) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
BTIG Downgrades Integra LifeSciences (IART) to Sell
July 29, 2024 4:10 PM EDTBTIG analyst Ryan Zimmerman downgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Sell with a price target of $22.00.
The analyst comments "We are downgrading to SELL following 2Q24 results, setting a $22 PT at 8.5x our 12-24 month EPS estimate. Another quarter and another negative update regarding IART's manufacturing and quality controls pushing out recovery to FY26. At the same time, IART's 2Q24 results were not bad. IART reported rev. of $418.2M (9.7%, 2.3% organic, 0.3% organic ex. Boston) and adj. EPS... More
